The current situation was known by Dec '09 - there have been no subsequent material surprises - the flight had already left the gate for its current destination. Biotech Qs are almost always about the IP - if they were ever about the currently approved products - they wouldn't be in bk. My guess on MBRK would be that they overestimated the penetration they'd get with Moxatag, and overhired on the sales force - bad move - thanks to the powers that be for bad moves or there would be no such thing as bankrupt pennystocks. There was focus on the NOLs in the first day motions - from my experience, trading restriction motions usually come later. This suggests to me that the framework is well worked out, and involves savings the NOLs - which means no 363 sale of IP. They've outsourced distribution on Moxatag - very little burn left. Could MBRK become a sort of outsourcing platform company with Pulsys? Big Pharma loves to 'evergreen' their blockbusters with soon to be expired patent protection - changing the formulation to once a day works for this purpose - MBRK becomes a value added service provider - and with the NOLs in place, there is no after tax profit margin to calculate.
News 
Market Data 
Discover 
AI
